Three months after Biomea Fusion’s menin inhibitor was released from a clinical hold, the company has claimed a win in…

After spending most of the year hunting for options to stay afloat, cash-strapped Portage Biotech appears to have found salvation…

Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy…

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace…

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline…

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial. The oral…

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed that it’s…

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped…

Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma,…

In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia…